Modification of the lipidic and coagulative pattern in postmenopause women: effect of hormone replacement therapy

被引:0
|
作者
Evola, G. [1 ]
Novo, G. [1 ]
Amoroso, G. [1 ]
Guttilla, D. [1 ]
Lo Coco, L. [2 ]
Guagliardo, M. [3 ]
Lupo, A. [3 ]
Averna, M. R. [4 ]
Giambanco, V. [3 ]
Miller, V. [5 ]
Novo, S. [2 ]
机构
[1] Univ Palermo, Div Cardiovasc Dis, Dept Internal Med & Cardiovasc Dis, Univ Hosp Paolo Giaccone, Palermo, Italy
[2] Univ Palermo, Div Haematol, Dept Internal Med & Cardiovasc Dis, Univ Hosp Paolo Giaccone,Lab Haemostasis & Thromb, Palermo, Italy
[3] ARNAS Hosp, Div Obstet & Gynaecol 2, Palermo, Italy
[4] Univ Palermo, Dept Internal Med & Emerging Pathol, Palermo, Italy
[5] Mayo Clin, Dept Surg Physiol & Biophys, Biochem Lab, Rochester, MN USA
关键词
Menopause; Hormone replacement therapy; Tissue factor pathway inhibitor; RANDOMIZED CONTROLLED-TRIAL; VENOUS THROMBOEMBOLISM; CARDIOVASCULAR-DISEASE; ESTROGEN THERAPY; HEART-DISEASE; RISK; HEALTH; PROGESTIN; HRT;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aim. We evaluated the changes of lipidic and coagulative pattern during menopause and the influence of hormone replacement therapy (HRT) on these parameters. Methods. We considered 158 patients divided into 2 groups: Group I consisted of 127 women in physiological/surgical menopause and Group II of 31 women with childbearing potential. Subsequently, we considered a group III formed of 34 patients from menopausal women (group I) who underwent three months of HRT. We evaluated total-cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), triglycerides (TG), lipoprotein (a) (Lpa), fibrinogen, antithrombin III (ATIII), factor VII (FVII) and tissue factor pathway inhibitor (TFPI). Results. We found a worse lipid profile in the postmenopausal group compared to controls (TC 243.8+/-29.7 vs 217.9+/-32.7 mg%, P=0.002; TG 121.5+/-68.4 vs 88.6+/-53.0 mg%, P=0.039; LDL-C 163.0+/-27.9 vs 136.2+/-29.6 mg%, P=0.004; HDL-C 60.9+/-14.9 vs 64.1+/-14.6 mg%, P=ns). With regard to the coagulative pattern, fibrinogen was significantly higher in the post-menopausal group (fibrinogen: 273.3+/-67.4 vs 243.8+/-39.5 mg%, P=0.013; ATIII 112.2+/-11.7 vs 117.5+/-12.7% %, P=0.059; FVII 121.6+/-11.3 vs 117.6+/-10.8 mg%, P=ns; TFPI activity 2.5+/-2.3 vs 2.1+/-1.1 U/mL, P=ns; TFPI antigen 120 38 vs 127 39 U/mL, P=ns). Comparing the same parameters, before and after three months of HRT, in patients of Group III we observed a significant improvement of TC and TG levels (TC from 232.3+/-42.7 to 215.2+/-37.6 mg%, P=0.0001; TG from 103.7+/-56.8 to 95.0+/-44.3 mg%, P=0.059; HDL-C from 62.3+/-12.9 to 63.6+/-12.6 mg%, P=ns; LDL-C from 149.3+/-38.7 to 132.6+/-34.5 mg%, P=0.0001). The following changes were observed with regard to coagulative parameters: fibrinogen from 270.9+/-69.4 to 253.2+/-56.2 mg%, P=0.07; ATIII from 113.5+/-11.4 to 110.8+/-13.2 mg%, P=0.198; FVII from 108.6+/-18.0 to 104.4+/-17.5 mg%, 0.014. TFPI activity from 2.6+/-2.3 to 2.3+/-1.4 U/ml, P=ns; TFPI antigen from 68 13 to 87 22 U/mL, P=0.001. Conclusions. Our data confirm the presence of an alteration in lipidic and coagulative pattern in post menopausal women and positive changes after HRT. [Int Angiol 2010;29:355-61]
引用
收藏
页码:355 / 361
页数:7
相关论文
共 50 条
  • [1] Hormone replacement therapy in postmenopause
    Keller, PJ
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1995, 256 : S193 - S197
  • [2] Effect of postmenopause and hormone replacement therapy on serum adiponectin levels
    Sieminska, L
    Wojciechowska, C
    Niedziolka, D
    Marek, B
    Kos-Kudla, B
    Kajdaniuk, D
    Nowak, M
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (12): : 1610 - 1614
  • [3] Hormone replacement therapy in peri- and postmenopause
    Henes, M.
    Huebner, S.
    INTERNIST, 2020, 61 (06): : 558 - 564
  • [4] Possibilities of androgens for hormone replacement therapy in postmenopause
    Felberbaum, R
    Ortmann, O
    Diedrich, K
    GYNAKOLOGE, 1998, 31 (10): : 896 - 901
  • [5] HORMONE REPLACEMENT THERAPY IN POSTMENOPAUSE AND CARDIOVASCULAR DISEASES
    Salobir, Barbara Guzic
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2008, 77 : 33 - 37
  • [6] ORAL DISCOMFORT AND HORMONE REPLACEMENT THERAPY IN THE POSTMENOPAUSE
    VOLPE, A
    LUCENTI, V
    FORABOSCO, A
    BOSELLI, F
    LATESSA, AM
    POZZO, P
    PETRAGLIA, F
    GENAZZANI, AR
    MATURITAS, 1991, 13 (01) : 1 - 5
  • [7] Psychosocial aspects of hormone replacement therapy in postmenopause
    Buddeberg, C
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1995, 256 : S198 - S203
  • [8] Effects of hormone replacement therapy on ocular function in postmenopause
    Affinito, P
    Sardo, AD
    Di Carlo, C
    Sammartino, A
    Tommaselli, GA
    Bifulco, G
    Loffredo, A
    Loffredo, M
    Nappi, C
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2003, 10 (05): : 482 - 487
  • [9] Hormone replacement therapy and mild cognitive impairment in postmenopause
    de Franciscis, P.
    Luisi, A.
    Matteo, M.
    Basso, A.
    Cerreto, V.
    Cicatiello, R.
    Marcello, A.
    Muscio, M. F.
    Vaccarella, L.
    Labriola, D.
    Colacurci, N.
    GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2013, 35 (03): : 457 - 461
  • [10] Sexual dysfunction in Chinese women at different reproductive stages and the positive effect of hormone replacement therapy in the early postmenopause
    Ju, Rui
    Ruan, Xiangyan
    Xu, Xin
    Yang, Yu
    Cheng, Jiaojiao
    Zhang, Luping
    Wang, Binhong
    Qin, Shuang
    Dou, Zhuli
    Mueck, Alfred O.
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2021, 26 (03): : 246 - 254